T. Mughal, N. Cross, E. Padron, R. Tiu, M. Savona et al., An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms, Haematologica, vol.100, issue.9, pp.1117-1147, 2015.
DOI : 10.3324/haematol.2014.114660

P. Fenaux and L. Ades, How we treat lower-risk myelodysplastic syndromes, Blood, vol.121, issue.21, pp.4280-4286, 2013.
DOI : 10.1182/blood-2013-02-453068

M. Cazzola, D. Porta, M. Malcovati, and L. , The genetic basis of myelodysplasia and its clinical relevance, Blood, vol.122, issue.25, pp.4021-4055, 2013.
DOI : 10.1182/blood-2013-09-381665

T. Haferlach, Y. Nagata, V. Grossmann, Y. Okuno, U. Bacher et al., Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia, vol.82, issue.2, pp.241-248, 2014.
DOI : 10.1038/leu.2013.336

H. Hajkova, M. Fritz, C. Haskovec, J. Schwarz, C. Salek et al., CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia, Journal of Hematology & Oncology, vol.11, issue.11, p.66, 2014.
DOI : 10.1186/s13045-014-0066-4

L. Malcovati, E. Papaemmanuil, I. Ambaglio, C. Elena, A. Galli et al., Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia, Blood, vol.124, issue.9, pp.1513-1534, 2014.
DOI : 10.1182/blood-2014-03-560227

C. Ok, K. Patel, G. Garcia-manero, M. Routbort, J. Peng et al., TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases, Journal of Hematology & Oncology, vol.116, issue.1, p.45, 2015.
DOI : 10.1186/s13045-015-0139-z

E. Papaemmanuil, M. Gerstung, L. Malcovati, S. Tauro, G. Gundem et al., Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, vol.122, issue.22, pp.3616-3643, 2013.
DOI : 10.1182/blood-2013-08-518886

K. Skvarova, K. Fiser, E. Mejstrikova, K. Rejlova, M. Zaliova et al., Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations, Journal of Hematology & Oncology, vol.17, issue.1, p.94, 2014.
DOI : 10.1186/s13045-014-0094-0

V. Visconte, A. Tabarroki, L. Zhang, Y. Parker, E. Hasrouni et al., Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts, Journal of Hematology & Oncology, vol.27, issue.1, p.89, 2014.
DOI : 10.1186/s13045-014-0089-x

H. Wang, J. Wen, C. Chang, and X. Zhou, Discovering Transcription and Splicing Networks in Myelodysplastic Syndromes, PLoS ONE, vol.67, issue.11, p.79118, 2013.
DOI : 10.1371/journal.pone.0079118.s001

G. Chen, W. Zeng, A. Miyazato, E. Billings, J. Maciejewski et al., Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities, Blood, vol.104, issue.13, pp.4210-4218, 2004.
DOI : 10.1182/blood-2004-01-0103

M. Dellett, O. Hagan, K. Colyer, H. Mills, and K. , Identification of gene networks associated with acute myeloid leukemia by comparative molecular methylation and expression profiling, Biomark Cancer, vol.2, pp.43-55, 2010.

H. Dolatshad, A. Pellagatti, M. Fernandez-mercado, B. Yip, L. Malcovati et al., Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells, Leukemia, vol.29, issue.5, pp.1092-103, 2015.
DOI : 10.1016/j.febslet.2013.05.030

N. Galili and A. Raza, Clinical implications of gene expression profiling in myelodysplastic syndromes: Recognition of ribosomal and translational gene dysregulation and development of predictive assays, Best Practice & Research Clinical Haematology, vol.22, issue.2, pp.223-260, 2009.
DOI : 10.1016/j.beha.2009.04.006

M. Gerstung, A. Pellagatti, L. Malcovati, A. Giagounidis, M. Porta et al., Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes, Nature Communications, vol.2, p.5901, 2015.
DOI : 10.1038/ncomms6901

W. Hofmann, S. De-vos, M. Komor, D. Hoelzer, W. Wachsman et al., Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow, Blood, vol.100, issue.10, pp.3553-60, 2002.
DOI : 10.1182/blood.V100.10.3553

L. Li, M. Li, C. Sun, L. Francisco, S. Chakraborty et al., Altered Hematopoietic Cell Gene Expression Precedes Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia and Identifies Patients at Risk, Cancer Cell, vol.20, issue.5, pp.591-605, 2011.
DOI : 10.1016/j.ccr.2011.09.011

A. Pellagatti, M. Cazzola, A. Giagounidis, J. Perry, L. Malcovati et al., Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells, Leukemia, vol.12, issue.4, pp.756-64, 2010.
DOI : 10.1007/s00018-009-9153-z

A. Pellagatti, A. Benner, K. Mills, M. Cazzola, A. Giagounidis et al., Identification of Gene Expression???Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.31, issue.28, pp.313557-64, 2013.
DOI : 10.1200/JCO.2012.45.5626

K. Sridhar, D. Ross, R. Tibshirani, A. Butte, and P. Greenberg, Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression, Blood, vol.114, issue.23, pp.4847-58, 2009.
DOI : 10.1182/blood-2009-08-236422

E. Taskesen, M. Havermans, K. Van-lom, M. Sanders, Y. Van-norden et al., Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling, Blood, vol.123, issue.21, pp.3327-3362, 2014.
DOI : 10.1182/blood-2013-07-512855

K. Theilgaard-monch, J. Boultwood, S. Ferrari, K. Giannopoulos, J. Hernandez-rivas et al., Gene expression profiling in MDS and AML: potential and future avenues, Leukemia, vol.114, issue.6, pp.909-929, 2011.
DOI : 10.1182/blood-2009-01-202606

S. Beurlet, C. Chomienne, and R. Padua, Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?, Haematologica, vol.98, issue.1, pp.10-22, 2013.
DOI : 10.3324/haematol.2012.069385

D. Chau, K. Ng, T. Chan, Y. Cheng, B. Fong et al., Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9, Journal of Hematology & Oncology, vol.87, issue.1, p.46, 2015.
DOI : 10.1186/s13045-015-0143-3

T. Zhou, M. Kinney, L. Scott, S. Zinkel, and V. Rebel, Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research, Blood, vol.126, issue.9, pp.1057-68, 2015.
DOI : 10.1182/blood-2015-01-624239

M. Raaijmakers, S. Mukherjee, S. Guo, S. Zhang, T. Kobayashi et al., Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia, Nature, vol.102, issue.7290, pp.852-859, 2010.
DOI : 10.1038/nature08851

S. Beurlet, N. Omidvar, P. Gorombei, P. Krief, L. Pogam et al., BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells, Blood, vol.122, issue.16, pp.2864-76, 2013.
DOI : 10.1182/blood-2012-07-445635

L. Pogam, C. Krief, P. Beurlet, S. Soulie, A. Balitrand et al., Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes, Leukemia Research, vol.37, issue.3, pp.312-321, 2013.
DOI : 10.1016/j.leukres.2012.10.018

L. Pogam, C. Patel, S. Gorombei, P. Guerenne, L. Krief et al., DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies, Oncotarget, vol.6, issue.32, pp.32494-508, 2015.

N. Omidvar, S. Kogan, S. Beurlet, L. Pogam, C. Janin et al., BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia, Cancer Research, vol.67, issue.24, pp.11657-67, 2007.
DOI : 10.1158/0008-5472.CAN-07-0196

R. Padua, B. Guinn, A. Sabah, M. Smith, C. Taylor et al., RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up, Leukemia, vol.12, issue.6, pp.887-92, 1998.
DOI : 10.1038/sj.leu.2401044

J. Parker, G. Mufti, F. Rasool, A. Mijovic, S. Devereux et al., The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS, Blood, vol.96, issue.12, pp.3932-3940, 2000.

F. Rassool, T. Gaymes, N. Omidvar, N. Brady, S. Beurlet et al., Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia?, Cancer Research, vol.67, issue.18, pp.8762-71, 2007.
DOI : 10.1158/0008-5472.CAN-06-4807

J. Luo, N. Solimini, and S. Elledge, Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction, Cell, vol.136, issue.5, pp.823-860, 2009.
DOI : 10.1016/j.cell.2009.02.024

E. Terpos, E. Verrou, A. Banti, V. Kaloutsi, A. Lazaridou et al., Bortezomib is an effective agent for MDS/MPD syndrome with 5q??? anomaly and thrombocytosis, Leukemia Research, vol.31, issue.4, pp.559-62, 2007.
DOI : 10.1016/j.leukres.2006.05.018

Y. Yue, Y. Wang, Y. He, S. Yang, Z. Chen et al., Reversal of Bortezomib Resistance in Myelodysplastic Syndrome Cells by MAPK Inhibitors, PLoS ONE, vol.25, issue.3, p.90992, 2014.
DOI : 10.1371/journal.pone.0090992.g010

D. Benjamin, A. Cozzo, J. X. Roberts, L. Louie, S. Mulvihill et al., Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity, Proceedings of the National Academy of Sciences, vol.110, issue.37, pp.14912-14919, 2013.
DOI : 10.1073/pnas.1310894110

K. Eisenmann, K. Dykema, S. Matheson, N. Kent, A. Deward et al., 5q??? myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics, Oncogene, vol.14, issue.39, pp.3429-3470, 2009.
DOI : 10.1038/onc.2009.207

M. Nyakern, P. Tazzari, C. Finelli, C. Bosi, M. Follo et al., Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients, Leukemia, vol.19, issue.2, pp.230-238, 2006.
DOI : 10.1038/sj.leu.2404057

I. Franco, F. Gulluni, C. Campa, C. Costa, J. Margaria et al., PI3K Class II ?? Controls Spatially Restricted Endosomal PtdIns3P and Rab11 Activation to Promote Primary Cilium Function, Developmental Cell, vol.28, issue.6, pp.647-58, 2014.
DOI : 10.1016/j.devcel.2014.01.022

O. Fuchs, D. Provaznikova, M. Kocova, A. Kostecka, P. Cvekova et al., CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma, Blood Cells, Molecules, and Diseases, vol.40, issue.3, pp.401-406, 2008.
DOI : 10.1016/j.bcmd.2007.11.005

P. Fenaux, A. Giagounidis, D. Selleslag, O. Beyne-rauzy, G. Mufti et al., A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q, Blood, vol.118, issue.14, pp.3765-76, 2011.
DOI : 10.1182/blood-2011-01-330126

A. Raza, M. Mehdi, M. Mumtaz, F. Ali, S. Lascher et al., Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia, Cancer, vol.84, issue.7, pp.1596-604, 2008.
DOI : 10.1002/cncr.23789

R. Sood, I. Makalowska, J. Carpten, C. Robbins, D. Stephan et al., The human RGL (RalGDS-like) gene: cloning, expression analysis and genomic organization, Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol.1491, issue.1-3, pp.1-3285, 2000.
DOI : 10.1016/S0167-4781(00)00031-2

K. Schenkova, J. Lutz, M. Kopp, S. Ramos, and F. Rivero, MUF1/Leucine-Rich Repeat Containing 41 (LRRC41), a Substrate of RhoBTB-Dependent Cullin 3 Ubiquitin Ligase Complexes, Is a Predominantly Nuclear Dimeric Protein, Journal of Molecular Biology, vol.422, issue.5, pp.659-73, 2012.
DOI : 10.1016/j.jmb.2012.06.016

T. Maeda, F. Yagasaki, M. Ishikawa, N. Takahashi, and M. Bessho, Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML, Blood, vol.105, issue.5, pp.2115-2138, 2005.
DOI : 10.1182/blood-2003-12-4290

D. Ross, Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome, Best Practice & Research Clinical Haematology, vol.17, issue.4, pp.641-51, 2004.
DOI : 10.1016/S1521-6926(04)00080-5

V. Steimle, D. B. Barras, E. Zufferey, M. Hadam, M. Mach et al., A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)., Genes & Development, vol.9, issue.9, pp.1021-1053, 1995.
DOI : 10.1101/gad.9.9.1021

M. Fukuda, T. Sato, J. Nakayama, G. Klier, M. Mikami et al., Trophinin and tastin, a novel cell adhesion molecule complex with potential involvement in embryo implantation., Genes & Development, vol.9, issue.10, pp.1199-210, 1995.
DOI : 10.1101/gad.9.10.1199

K. Bettermann, M. Benesch, S. Weis, and J. Haybaeck, SUMOylation in carcinogenesis, Cancer Letters, vol.316, issue.2, pp.113-138, 2012.
DOI : 10.1016/j.canlet.2011.10.036

C. Pan, P. Baum, M. Gu, E. Jorgensen, S. Clark et al., C. elegans AP-2 and Retromer Control Wnt Signaling by Regulating MIG-14/Wntless, Developmental Cell, vol.14, issue.1, pp.132-141, 2008.
DOI : 10.1016/j.devcel.2007.12.001
URL : https://hal.archives-ouvertes.fr/in2p3-00115430

K. Pavlaki, C. Pontikoglou, A. Demetriadou, A. Batsali, A. Damianaki et al., Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway, Stem Cells and Development, vol.23, issue.14, pp.1568-81, 2014.
DOI : 10.1089/scd.2013.0283

M. Bar, D. Stirewalt, E. Pogosova-agadjanyan, V. Wagner, T. Gooley et al., Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression, Transl Oncogenomics, vol.3, pp.137-186, 2008.

H. Gal, N. Amariglio, L. Trakhtenbrot, J. Jacob-hirsh, O. Margalit et al., Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells, Leukemia, vol.130, issue.12, pp.2147-54, 2006.
DOI : 10.1038/sj.leu.2404401

C. Jamieson, I. Weissman, and E. Passegue, Chronic versus acute myelogenous leukemia, Cancer Cell, vol.6, issue.6, pp.531-534, 2004.
DOI : 10.1016/j.ccr.2004.12.005

F. Roversi, M. Lopes, J. Machado-neto, A. Longhini, A. Duarte et al., Serine Protease Inhibitor Kunitz-Type 2 Is Downregulated in Myelodysplastic Syndromes and Modulates Cell???Cell Adhesion, Stem Cells and Development, vol.23, issue.10, pp.1109-1129, 2014.
DOI : 10.1089/scd.2013.0441

S. Movafagh, S. Crook, and K. Vo, Regulation of Hypoxia-Inducible Factor-1a by Reactive Oxygen Species : New Developments in an Old Debate, Journal of Cellular Biochemistry, vol.72, issue.(4), pp.696-703, 2015.
DOI : 10.1002/jcb.25074

D. Arvanitis and D. Spandidos, Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study, Oncol Rep, vol.20, issue.4, pp.751-60, 2008.

G. Saberwal, E. Broderick, I. Janssen, V. Shetty, S. Alvi et al., Involvement of Cyclin D1 and E2F1 in Intramedullary Apoptosis in Myelodysplastic Syndromes, Journal of Hematotherapy & Stem Cell Research, vol.12, issue.4, pp.443-50, 2003.
DOI : 10.1089/152581603322286079

H. Tong, C. Hu, Z. Zhuang, L. Wang, and J. J. , Hypoxia-inducible factor-1?? expression indicates poor prognosis in myelodysplastic syndromes, Leukemia & Lymphoma, vol.72, issue.12, pp.2412-2420, 2012.
DOI : 10.1038/sj.leu.2405053

K. Veraldi, G. Arhin, K. Martincic, L. Chung-ganster, J. Wilusz et al., hnRNP F Influences Binding of a 64-Kilodalton Subunit of Cleavage Stimulation Factor to mRNA Precursors in Mouse B Cells, Molecular and Cellular Biology, vol.21, issue.4, pp.1228-1266, 2001.
DOI : 10.1128/MCB.21.4.1228-1238.2001

J. Boultwood, A. Pellagatti, M. Nikpour, B. Pushkaran, C. Fidler et al., The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts, PLoS ONE, vol.80, issue.4, p.1970, 2008.
DOI : 10.1371/journal.pone.0001970.t001

G. Mazzoccoli, C. De, A. Piepoli, and M. Vinciguerra, The circadian clock and the hypoxic response pathway in kidney cancer, Tumor Biology, vol.46, issue.4, pp.1-7, 2014.
DOI : 10.1007/s13277-013-1076-5

G. Mazzoccoli, M. Vinciguerra, G. Papa, and A. Piepoli, Circadian clock circuitry in colorectal cancer, World Journal of Gastroenterology, vol.20, issue.15, pp.4197-207, 2014.
DOI : 10.3748/wjg.v20.i15.4197

M. Baratti, Y. Moreira, F. Traina, F. Costa, S. Verjovski-almeida et al., Identification of protein-coding and non-coding RNA expression profiles in CD34+and in stromal cells in refractory anemia with ringed sideroblasts, BMC Medical Genomics, vol.18, issue.1, p.30, 2010.
DOI : 10.1097/MOL.0b013e3282ef77d1

R. Bhatia and H. Deeg, Treatment-related myelodysplastic syndrome: molecular characteristics and therapy, Current Opinion in Hematology, vol.18, issue.2, pp.77-82, 2011.
DOI : 10.1097/MOH.0b013e328343997a

N. Chapuis, J. Tamburini, P. Cornillet-lefebvre, L. Gillot, V. Bardet et al., Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody, Haematologica, vol.95, issue.3, pp.415-438, 2010.
DOI : 10.3324/haematol.2009.010785

F. Heredia, J. De-sousa, R. Junior, H. Carvalho, A. Magalhaes et al., Proteins related to the spindle and checkpoint mitotic emphasize the different pathogenesis of hypoplastic MDS, Leukemia Research, vol.38, issue.2, pp.218-242, 2014.
DOI : 10.1016/j.leukres.2013.11.003

A. Khanna-gupta, Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP??), Blood Cells, Molecules, and Diseases, vol.41, issue.1, pp.77-81, 2008.
DOI : 10.1016/j.bcmd.2008.02.011

C. Maratheftis, S. Giannouli, M. Spachidou, G. Panayotou, and M. Voulgarelis, RNA Interference of Interferon Regulatory Factor-1 Gene Expression in THP-1 Cell Line Leads to Toll-Like Receptor-4 Overexpression/Activation As Well As Up-modulation of Annexin-II, Neoplasia, vol.9, issue.12, pp.1012-1032, 2007.
DOI : 10.1593/neo.07640

H. Mjahed, F. Girodon, M. Fontenay, and C. Garrido, Heat shock proteins in hematopoietic malignancies, Experimental Cell Research, vol.318, issue.15, pp.1946-58, 2012.
DOI : 10.1016/j.yexcr.2012.05.012

H. Qi, L. Xiao, W. Lingyun, T. Ying, L. Yi-zhi et al., Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis, Annals of Hematology, vol.64, issue.23, pp.95-101, 2006.
DOI : 10.1007/s00277-005-0031-y

M. Sukhai, S. Prabha, R. Hurren, A. Rutledge, A. Lee et al., Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors, Journal of Clinical Investigation, vol.123, issue.1, pp.315-343, 2013.
DOI : 10.1172/JCI64180DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533286

K. Van-der-putten, B. Koch, E. Van-someren, J. Wielders, T. Wee et al., The role of renal function loss on circadian misalignment of cytokines EPO, IGF-1, IL-6 and TNF-alfa in chronic renal disease, Neuro Endocrinol Lett, vol.32, issue.2, pp.148-53, 2011.

S. Kogan, J. Ward, M. Anver, J. Berman, C. Brayton et al., Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice, Blood, vol.100, issue.1, pp.238-283, 2002.
DOI : 10.1182/blood.V100.1.238

P. Mombaerts, J. Iacomini, R. Johnson, K. Herrup, S. Tonegawa et al., RAG-1-deficient mice have no mature B and T lymphocytes, Cell, vol.68, issue.5, pp.869-77, 1992.
DOI : 10.1016/0092-8674(92)90030-G

A. Fan, D. Deb-basu, M. Orban, J. Gotlib, Y. Natkunam et al., Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens, Nature Medicine, vol.31, issue.5, pp.566-71, 2009.
DOI : 10.1038/nm.1903

P. De-la-grange, M. Dutertre, N. Martin, and D. Auboeuf, FAST DB: a website resource for the study of the expression regulation of human gene products, Nucleic Acids Research, vol.33, issue.13, pp.4276-84, 2005.
DOI : 10.1093/nar/gki738

P. De-la-grange, L. Gratadou, M. Delord, M. Dutertre, and D. Auboeuf, Splicing factor and exon profiling across human tissues, Nucleic Acids Research, vol.38, issue.9, pp.2825-2863, 2010.
DOI : 10.1093/nar/gkq008

P. De-la-grange, M. Dutertre, M. Correa, and D. Auboeuf, A new advance in alternative splicing databases: from catalogue to detailed analysis of regulation of expression and function of human alternative splicing variants, BMC Bioinformatics, vol.8, issue.1, p.180, 2007.
DOI : 10.1186/1471-2105-8-180

D. Huang, B. Sherman, and R. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nature Protocols, vol.99, issue.1, pp.44-57, 2009.
DOI : 10.1038/nprot.2008.211

D. Huang, B. Sherman, and R. Lempicki, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Research, vol.37, issue.1, pp.1-13, 2009.
DOI : 10.1093/nar/gkn923

V. Mootha, C. Lindgren, K. Eriksson, A. Subramanian, S. Sihag et al., PGC-1??-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, Nature Genetics, vol.34, issue.3, pp.267-73, 2003.
DOI : 10.1038/ng1180

A. Subramanian, P. Tamayo, V. Mootha, S. Mukherjee, B. Ebert et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proceedings of the National Academy of Sciences, vol.102, issue.43, pp.15545-50, 2005.
DOI : 10.1073/pnas.0506580102

P. Greenberg, C. Cox, M. Lebeau, P. Fenaux, P. Morel et al., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, vol.89, issue.6, pp.2079-88, 1997.

J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz et al., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-51, 2009.
DOI : 10.1182/blood-2009-03-209262